Younger Age, Earlier Disease Onset Predict Benign MS Course Younger Age, Earlier Disease Onset Predict Benign MS Course
A benign course of multiple sclerosis is rare, but a 5-year study shows younger patient age, earlier disease onset, female gender, and other factors may predict which MS cases will be benign.Medscape Medical News
ConclusionIn our cohort, NTZ associated IRR mainly occurred during the infusion period compared to the one-hour observational period. Also, the first IRR exclusively occurred within the first 4 NTZ administrations. However, further multi-center studies with a larger sample size are needed to capture rare and serious events that could emerge during the observational period and to make clinical recommendations.
What can we expect from the flu season this year? Unfortunately, many experts are predicting an active, and possibly severe, flu season. This projection is based on data from Australia, where the flu season is just wrapping up. Australia was hit early and hard by flu this year: over 300,000 patients had laboratory-confirmed influenza, a record number of cases. Flu outbreaks in the Southern Hemisphere happen during our summers, and they often give us a clue as to what we should expect when the flu lands on our shores in the fall. Who should get the flu vaccine? Basically, everybody over the age of 6 months, except for those...
The U.S. Food and Drug Administration on Wednesday approved Biogen Inc's new oral drug to treat multiple sclerosis, offering the drugmaker some relief as its core franchise faces patent challenges.Reuters Health Information
We present a patient where interferon-beta1a (IFN β1a) appears to amplify adverse effects of venom immunotherapy (VIT) and diminish desensitization. IFNβ1a is a disease modifying therapy for relapsing/remitting multiple sclerosis (MS). Her case is further complicated by her high sting risk occupation and living in a rural setting requiring helico pter transport for medical care.
We describe successful desensitization of two patients with immediate hypersensitivity reactions to Ocrelizumab.
Diroximel fumarate showed better GI tolerability compared with dimethyl fumarate in patients with relapsing forms of multiple sclerosis in the EVOLVE-MS-2 phase 3 study.FDA Approvals
The promise of serum neurofilament light chain to diagnose multiple sclerosis continues to evolve, with new evidence supporting a role in identifying presymptomatic disease.Medscape Medical News
A new B cell-depleting therapy, given as a monthly subcutaneous injection, has shown impressive results in two phase 3 studies in relapse-remitting multiple sclerosis.Medscape Medical News
A first of its kind observational study compares effectiveness of initial treatment choices for children and adolescents with multiple sclerosis — and finds an advantage for newer agents.Medscape Medical News
Atopic dermatitis (AD) is associated with a wide range of comorbidities, particularly allergies, but its association with nonatopic autoimmune disease is less well defined. Recent genome-wide association studies have reported shared genetic loci between AD and autoimmune diseases. In the UK, most patients with these conditions are managed in primary care, meaning general practice (GP) databases provide a rich data source for studying AD. A retrospective cohort study was undertaken to examine the association between AD and the following autoimmune diseases (rheumatoid arthritis [RA], ulcerative colitis [UC], Crohn ’s ...